WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H531862
CAS#: 325850-81-5
Description: GRI977143 is a selective lysophosphatidic acid 2 (LPA2) receptor non-lipid agonist (EC50 = 3.3 μM). GRI977143 does not activate other LPA GPCRs at concentrations up to 10 μM.
Hodoodo Cat#: H531862
Name: GRI977143
CAS#: 325850-81-5
Chemical Formula: C22H17NO3S
Exact Mass: 375.09
Molecular Weight: 375.442
Elemental Analysis: C, 70.38; H, 4.56; N, 3.73; O, 12.78; S, 8.54
Synonym: GRI977143; GRI-977143; GRI 977143.
IUPAC/Chemical Name: 2-[3-(1,3-dioxobenzo[de]isoquinolin-2-yl)propylsulfanyl]benzaldehyde
InChi Key: IYUOFUODBWFCBK-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H17NO3S/c24-14-16-6-1-2-11-19(16)27-13-5-12-23-21(25)17-9-3-7-15-8-4-10-18(20(15)17)22(23)26/h1-4,6-11,14H,5,12-13H2
SMILES Code: O=CC1=CC=CC=C1SCCCN(C(C2=CC=CC3=CC=CC4=C23)=O)C4=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 375.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Lin KH, Ho YH, Chiang JC, Li MW, Lin SH, Chen WM, Chiang CL, Lin YN, Yang YJ, Chen CN, Lu J, Huang CJ, Tigyi G, Yao CL, Lee H. Pharmacological activation of lysophosphatidic acid receptors regulates erythropoiesis. Sci Rep. 2016 May 31;6:27050. doi: 10.1038/srep27050. PubMed PMID: 27244685; PubMed Central PMCID: PMC4886675.
2: Kiss GN, Lee SC, Fells JI, Liu J, Valentine WJ, Fujiwara Y, Thompson KE, Yates CR, Sümegi B, Tigyi G. Mitigation of radiation injury by selective stimulation of the LPA(2) receptor. Biochim Biophys Acta. 2013 Jan;1831(1):117-25. doi: 10.1016/j.bbalip.2012.08.020. PubMed PMID: 23127512; PubMed Central PMCID: PMC3491361.
3: Kiss GN, Fells JI, Gupte R, Lee SC, Liu J, Nusser N, Lim KG, Ray RM, Lin FT, Parrill AL, Sümegi B, Miller DD, Tigyi G. Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol. 2012 Dec;82(6):1162-73. doi: 10.1124/mol.112.079699. PubMed PMID: 22968304; PubMed Central PMCID: PMC3502618.